Why the study?
The appropriate dose of aspirin to reduce death, myocardial infarction, and stroke while minimizing major bleeding in patients with established atherosclerotic cardiovascular disease remains controversial.
Does aspirin 81 mg per day reduce cardiovascular events or major bleeding compared to 325 mg per day in patients with established atherosclerotic cardiovascular disease?
Does aspirin 81 mg per day reduce cardiovascular events or major bleeding compared to 325 mg per day in patients with established atherosclerotic cardiovascular disease?
In patients with established atherosclerotic cardiovascular disease, a strategy of 81 mg daily aspirin resulted in similar cardiovascular and bleeding outcomes compared to 325 mg daily, though the 325 mg group experienced substantial dose switching.
No takes yet. Share an insight, caveat, or question.
Supports either aspirin dose for ASCVD patients; confirms no CV benefit of 325 mg over 81 mg daily.
Jones et al. (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: